Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid

Francesca Curreli [a], Hongtao Zhang [a], Xihui Zhang [a], Ilya Pyatkin [b], Zagorodnikov Victor [b], Andrea Altieri [b], Asim K. Debnath [a,*]

[a] Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute of the New York Blood Center, 310 E 67th Street, New York, NY 10065, USA
[b] Asinex, 20 Geroev Panfilovtzev, Building 1, Moscow 125480, Russia

ARTICLE INFO

ABSTRACT

The hydrophobic cavity of the C-terminal domain (CTD) of HIV-1 capsid has been recently validated as potential target for antiviral drugs by peptide-based inhibitors; however, there is no report yet of any small molecule compounds that target this hydrophobic cavity. In order to fill this gap and discover new classes of ant-HIV-1 inhibitors, we undertook a docking-based virtual screening and subsequent analog search, and medicinal chemistry approaches to identify small molecule inhibitors against this target. This article reports for the first time, to the best of our knowledge, identification of diverse classes of inhibitors that efficiently inhibited the formation of mature-like viral particles verified under electron microscope (EM) and showed potential as anti-HIV-1 agents in a viral infectivity assay against a wide range of laboratory-adapted as well as primary isolates in MT-2 cells and PBMC. In addition, the virions produced after the HIV-1 infected cells were treated with two of the most active compounds showed drastically reduced infectivity confirming the potential of these compounds as anti-HIV-1 agents. We have derived a comprehensive SAR from the antiviral data. The SAR analyses will be useful in further optimizing the leads to potential anti-HIV-1 agents.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

The HIV-1 genome is composed of three major genes, *gag*, *pol*, and *env*. The *gag* gene encodes the Gag protein, the critical structural protein of HIV-1, whereas *pol* encodes the viral enzymes reverse transcriptase (RT), protease (PR), and integrase (IN), essential for the HIV-1 replication. During HIV-1 assembly and morphogenesis, the structural protein, Gag, organizes into two completely different arrangements, immature, and mature forms. In the immature form, Gag remains intact, whereas in the mature form Gag is cleaved by the viral protease. The formation of this mature particle is essential for HIV-1 infectivity and the capsid protein obtained from the Gag cleavage product plays a central role in forming the conical core of the virus that surrounds the viral genome. The capsid protein (CA, p24) is a hydrophobic protein consisting of two domains, the N-terminal domain (NTD, aa 1–145) and the C-terminal domain (CTD, aa 146–231). These two domains are connected with a 5-amino acid linker. Although the exact nature of the CA–CA contacts and their interactions in immature particles are not fully known, in mature particles the CA lattice has

been modeled based on structural studies and image reconstructions by cryo-electron microscopy of mature virions and assembled VLPs.[1–4] Recently, a pseudo-atomic model of the full-length HIV-1 capsid hexameric structure has been reported, which provided structural insights on the mechanism of action of some known assembly inhibitors.[5] HIV-1 capsid plays a crucial role in viral assembly, maturation, and also early post-entry steps.[1–4,6] Mutations in both the NTD and CTD lead to defects in viral assembly and release.[7–18] In addition, capsid has been shown to be a dominant determinant of HIV-1 infectivity in non-dividing cells.[19] Taken together, it is evident that capsid plays an important role in HIV-1 assembly and maturation, and has been recognized as a potential target for developing a new generation of drugs for AIDS therapy.[20–22]

Several peptides and small molecules that disrupt HIV-1 assembly have been reported in the literature.[23–28] The first breakthrough in identifying small-molecule inhibitors (CAP-1 and CAP-2) targeted to the NTD of capsid was reported by Summers's group.[26] These compounds affect virus stability and/or assembly. Only CAP-1 showed dose-dependent HIV-1 inhibition in viral infectivity assays, while CAP-2 was cytotoxic. Although the affinity of CAP-1 for the NTD was low ($K_d \sim 800$ μM) it serves as a lead compound for more potent inhibitors against this target. Recently, the

78

F. Curreli et al. / Bioorg. Med. Chem. 19 (2011) 77–90

structure of CAP-1 in complex with the NTD has been solved.[29] A small-molecule inhibitor, PA-457, which blocks HIV-1 maturation by inhibiting CA-SP1 cleavage, has been recently reported.[28,30–35] PA-457 has shown low nM antiviral potency in cell culture, providing credence to the hypothesis that highly potent inhibitors to Gag can be identified despite the fact that literally thousands of copies of Gag are present in a virion. This compound is currently in Phase 2b clinical trials (http://www.myriadpharma.com/product-pipeline/clinical/mpc-4326). Recently, a 12-mer peptide, CAI, was identified by phage-display technique and shown to inhibit HIV-1 assembly in vitro by targeting the CTD.[36] CAI was the first peptide reported to disrupt both immature- and mature-like particles in vitro. However, CAI could not inhibit HIV-1 in cell culture due to its lack of cell permeability and hence could not consider as a viable drug candidate.

Recently, we successfully applied the hydrocarbon stapling technique[37] to convert CAI to a cell-penetrating peptide (NYAD-1), which binds to the CTD. The stapling technique involves the introduction of two α,α-disubstituted non-natural amino acids containing terminal olefinic side chains at positions i and (i + 4) or (i + 7) and cyclized using ruthenium catalyzed metathesis reaction to create the stapled peptides. NYAD-1 disrupts the formation of both immature- and mature-like virus particles in cell-free and cell-based in vitro assembly systems. In addition, NYAD-1 displays potent anti-HIV-1 activity in cell culture against a range of laboratory-adapted and primary HIV-1 isolates. It binds to a hydrophobic cavity identified previously in X-ray studies of CTD complexed with CAI[38] with an improved affinity (K_d ~1 μM) compared to CAI (K_d ~15 μM).[39] In this study, we have exploited the same hydrophobic cavity as a target to identify organic small molecule inhibitors using a docking-based virtual screening approach followed by synthetic medicinal chemistry. We have identified several small molecule inhibitors which may serve as effective leads against this target for further optimization.

2. Results

2.1. Virtual screening

The binding site of the first reported peptide, CAI, was mapped in an NMR chemical shift perturbation study to a highly conserved hydrophobic cavity formed by residues 169–191 of CTD of HIV-1 capsid.[36,38] This was also confirmed by a high-resolution x-ray structure analysis of the CAI structure in complex with the CTD[38] (PDB code: 2buo), which revealed the molecular details of the interaction of this peptide in the hydrophobic cavity. Our recent NMR structure of the next generation peptide-based inhibitor, NYAD-1, also demonstrated that it bound to the same region of the CTD (aa 169–192).[40] These studies have provided us with a wealth of structural information on the binding mode of these inhibitors in the hydrophobic cavity and surrounding area. We wanted to exploit the same hydrophobic cavity to identify organic small molecules that might disrupt the formation and maturation of virus particles and inhibit virus infection. We have screened a subset of 100,000 drug-like molecules from the ZINC[41] database using virtual screening based on high-throughput flexible docking technique, which is becoming an emerging technology for structure-based rational lead discovery. We have selected 200 top-scored compounds for visual analysis using 3D stereoscopic glasses to identify compounds, which had the best possible interactions at the hydrophobic cavity of the CTD and selected 50 compounds for experiments. We have initially ordered 8 compounds from a vendor and tested their antiviral activity against HIV-1 IIIB. Two of the 8 compounds (**6** and **50**) belonging to two diverse scaffolds showed antiviral potency and one compound (**6**) was potent and had a selectivity index (SI) of >60 (SI = CC_{50}/IC_{50}; Table 3). Structures of selected few active compounds have been shown in Figure

1. A further search of analogs of these two hits from commercial sources resulted in additional compounds. Then we initiated medicinal chemistry on one of the active hits, **6** to derive a comprehensive SAR.

2.1.1. Compounds 6 and 50 both disrupt the formation of mature-like particles

We have characterized these compounds for their inhibitory effect on viral assembly and maturation. Spherical immature-like particles were formed by using full length gag proteins. The effect of inhibitors on immature- and mature-like particle assembly was studied by performing assembly reactions in the presence of varied doses of **6** and **50**. These compounds failed to disrupt immature-like particle formation even at molar equivalent dose (data not shown). Tube-shaped mature-like particles were obtained from purified CA as reported.[3,42] The rationale behind using CA instead of CANC to form the mature-like particles was to confirm that **6** and **50** target CA only.[39] In vitro data indicate that **6** and **50** disrupt the formation of mature-like particles (Fig. 2) in a dose-dependent manner as observed with the hydrocarbon-stapled peptide, NYAD-1[39], which was used as positive control. After incubation with 0.5-fold molar equivalents of **6**, the integrity of tube-like particles was greatly damaged. After incubation with one or five molar equivalent of **6**, the assembly of tube-shaped particles was completely blocked. In case of **50**, three molar equivalents completely disrupted the formation of tube-shaped particles.

2.2. Antiviral activity and cytotoxicity of small molecule compounds in cell-based assays

Since both **6** and **50** showed inhibition of mature-like particle assembly in cell-free assay we decided to test all similar compounds identified from database against a laboratory-adapted strain HIV-1 IIIB in MT-2 cells. The inhibition of p24 production by these molecules was measured over a range of concentrations to determine the IC_{50} values (concentration of inhibitor required to produce 50% reduction in p24 production). The results in Table 1 showed that the analogs of **6** showed very good activity ranging from 1.06 to 12.4 μM. Similarly, Table 2 indicated the activity

Figure 1. Chemical structures of selected inhibitors identified by docking-based virtual screening and similarity search techniques.

Figure 2. Inhibition of in vitro assembly by **6** and **50**. Negatively stained EM images of mature-like particles resulting from in vitro assembly of CA proteins in the presence of no inhibitors (control), 0.5-, 1.0-M equiv of NYAD-1 (positive control), **6** and **50**. Two higher doses were used in case of NYAD-1 (5.0-M equiv) and for **50** (3.0-M equiv) to reach complete inhibition.

ranges of the **50** type analogs tested. Although most of the compounds showed low to moderate activity two compounds (**50** and **55**) showed very good activity profile.

The encouraging data in the primary antiviral screening along with inhibition of mature-like particles by **6** and **50** motivated us to select these compounds to assess their antiviral activities in a wide variety of laboratory-adapted belonging to subtype B but different co-receptor use (X4, R5 and R5X4). The activities were assessed in two cell lines (MT-2 and PBMC). All three compounds showed excellent activity profiles (IC$_{50}$ ~1.06 to 7.09 μM; Table 3). In addition, we also tested these compounds against one RT-resistant and one protease-resistant strain. Remarkably, they all showed very similar activities as laboratory strains indicating their possible potential for further optimization as potential anti-HIV-1 agents with broad-spectrum activity.

We also tested these three molecules against a panel of primary isolates in PBMC representing diverse subtypes from A to O and diverse coreceptor use. The compounds showed excellent activity in all the primary isolates tested (0.73–5.46 μM) except group O (6.07–10.95 μM). Compounds **50** and **55** showed potent activity against one primary isolate (92UG037 under subtype A). All three compounds showed broad-spectrum activity (Table 3), which is very encouraging. This provides additional confidence that some of these lead molecules will be amenable for further modification to increase potency and selectivity.

The cytotoxicity of these compounds was assessed by the XTT method in either MT-2 cells or in both MT-2 cells and PBMC. Cytotoxicity assays were performed in parallel with the HIV-1 inhibition assays. The CC$_{50}$ (concentration of inhibitor required to produce 50% cytotoxicity) values for MT-2 and PBMC were presented in Tables 1–3.

2.3. Virions released from HIV-1 infected cells after treatment with the inhibitors are less infectious

Antiviral assays have shown a decrease in HIV-1 viral particle release by small molecules represented by reduction in p24 production (Tables 1–3). In addition, **6** and **50** effectively inhibited mature-like particles and prevented assembly in vitro (Fig. 3). Therefore, we reason that the effect of these molecules on newly generated virions is much greater than can be envisioned by the antiviral data. In other words, we believe that these molecules may possibly interfere with viral uncoating and viral assembly/maturation inducing irreparable damage to the viral particles newly produced and released in the supernatant, therefore, making them less infectious. To support our hypothesis we evaluated not only the quantity but also the quality of the virus progenies released in the supernatant using two of the most active compounds, **6** and **55**. We first quantified the p24/viral particles released in the supernatant following AMD3100 (positive control), **6** and/or **55** treatment then we treated cells with the identical amount of p24-normalized supernatants. However, it is pertinent to note that at higher doses of AMD3100, **6** and **55** we could detect very little to no p24 in the supernatants. Therefore, we used the maximum quantities of supernatants possible to infect MT-2 cells for measuring the infectivity of the virus progenies released in the supernatant. As expected, we detected no viral infectivity for samples treated with AMD3100 and with 5 μM of **6** and 4 μM of **55**

Table 1
Antiviral activity of **1** and its analogs against HIV-1 IIIB in MT-2 cells

No.	R₁	R₂	R₃	R₄	R₅	μM (±SD)	
						IC$_{50}$	CC$_{50}$
1	furan	phenyl	H	H	CH$_3$	4.02 ± 0.28	>67.13
2	furan	2-CH$_3$-phenyl	H	H	CH$_3$	4.23 ± 0.39	>64.7
3	furan	2-F-phenyl	H	H	CH$_3$	7.25 ± 0.54	>64
4	furan	thiophene	H	H	CH$_3$	>16.5	>66.1
5	furan	4-CH$_3$-phenyl	H	H	CH$_3$	2.67 ± 0.5	9.2 ± 1.0
6	furan	4-Cl-phenyl	CH$_3$	H	H	1.06 ± 0.05	>61.45
7	furan	pyridine	CH$_3$	H	H	>16.7	ND
8	furan	4-Br-phenyl	CH$_3$	H	H	2.16 ± 0.07	>55.4
9	furan	phenyl	CH$_3$	H	H	9.28 ± 0.68	>67.1
10	furan	CF$_3$	CH$_3$	H	H	>27.5	ND
11	furan	N-methylpiperazine	CH$_3$	H	H	>24.5	ND
12	furan	4-F-phenyl	CH$_3$	H	H	>25.6	ND

Table 1 (continued)

No.	R$_1$	R$_2$	R$_3$	R$_4$	R$_5$	μM (±SD)	
						IC$_{50}$	CC$_{50}$
13			CH$_3$	H	H	9.2 ± 0.7	70.7 ± 5.4
14			CH$_3$	H	H	>23.6	ND
15			CH$_3$	H	H	7.1 ± 0.4	>20.4
16			CH$_3$	H	H	>25.2	ND
17			CH$_3$	H	H	8.2 ± 1.2	>23.5
18			CH$_3$	H	H	>21.9	ND
19			CH$_3$	H	H	>24.8	ND
20			CH$_3$	H	H	>24.1	ND
21			CH$_3$	H	H	>23.6	ND
22			CH$_3$	H	H	>26.6	ND
23			CH$_3$	H	H	4.7 ± 0.6	>24.5

Table 1 (continued)

No.	R_1	R_2	R_3	R_4	R_5	μM (±SD)	
						IC$_{50}$	CC$_{50}$
24	2-furyl	4-(aminosulfonyl)phenyl	CH$_3$	H	H	>22.1	ND
25	tetrahydrofuran-2-yl	4-chlorophenyl	CH$_3$	H	H	>38.9	ND
26	4-chlorophenyl	8-methylimidazo[1,2-a]pyridin-2-yl	CH$_3$	H	H	9.27 ± 0.3	44.5 ± 5.5
27	2-furyl	phenyl	C$_2$H$_5$	H	H	>13.9	ND
28	2-furyl	2-thienyl	C$_2$H$_5$	H	H	12.3 ± 0.85	>127.4
29	2-furyl	4-bromophenyl	OCH$_3$	H	H	>13	ND
30	2-furyl	4-methylphenyl	OCH$_3$	H	H	7.87 ± 1.0	>31
31	2-furyl	phenyl	OCH$_3$	H	H	>25.7	ND
32	2-thienyl	cyclohexyl	CH$_3$	H	H	11.7 ± 1.2	>63.4
33	2-thienyl	2-thienyl	CH$_3$	H	H	11.8 ± 0.4	>64
34	2-thienyl	phenyl	CH$_3$	H	H	>12.9	ND
35	2-thienyl	4-(ethoxy)phenyl	CH$_3$	H	H	5.0 ± 0.2	12.7 ± 1.0
36	2-thienyl	2-methylphenyl	CH$_3$	H	CH$_3$	8.6 ± 1.1	>96

Table 1 (continued)

No.	R_1	R_2	R_3	R_4	R_5	μM (±SD)	
						IC_50	CC_50
37	*—S (thiophene)	*—phenyl-CH_3 (meta)	OCH_3	H	H	7.9 ± 0.4	25 ± 1.0
38	*—S (thiophene)	*—cyclohexyl	OCH_3	H	H	6.1 ± 0.7	>48
39	*—O (furan)	*—phenyl-C(CH_3)_3 (para, tert-butyl)	H	CH_3	H	>14.6	ND
40	*—O (furan)	*—phenyl-OCH_3 (para)	H	CH_3	H	>15	ND
41	*—O (furan)	*—phenyl	H	CH_3	H	>16.8	ND
42	*—O (furan)	*—phenyl-F (meta)	H	CH3	H	12.4 ± 0.6	>51.2
43	*—O (furan)	*—phenyl-CH_3 (para)	H	CH3	H	>16.2	ND
44	*—phenyl	*—phenyl-Cl (meta)	H	H	CH_3	3.59 ± 0.36	>60
45	*—phenyl	*—O (furan)	CH_3	H	H	3.09 ± 0.55	>67.13
46	*—phenyl-CH_3 (para)	*—O (furan)	CH_3	H	H	6.51 ± 0.94	>65
47	*—phenyl-CH_3 (para)	*—O (furan)	CH_3	H	H	6.4 ± 0.17	>19.8
48	*—benzodioxole	*—phenyl	CH_3	H	H	5.8 ± 0.36	>117

ND, not determined.

(Fig. 3). We calculated the TCID_50 considering only those doses which showed measurable infectivity. Infectivity efficiency of virus progenies was expressed as percentage of infectivity with respect to the untreated control. We detected about 60% of infectivity in the virus produced by the cells treated with 2.5 μM of **6** and 2 μM of **55**. Taken together these results suggest that **6** and **55**-treated virus-producing cells yield less infectious viruses; therefore, these molecules interfere with viral assembly and/or maturation.

2.4. Structure–activity relationship (SAR) analysis

Molecular docking-based virtual screening identified two compounds (**6**, Table 1) and (**50**, Table 2) with diverse chemical

Table 2
Antiviral activity of compound **49** and its analogs against HIV-1 IIIB in MT-2 cells

New No.	R	μM (± SD)	
		IC$_{50}$	CC$_{50}$
49	(phenyl)-NH-*	33.5[a]	>134.41
50	F-(phenyl)-NH-*	6.69 ± 0.3	>128.08
51	H$_3$C-C(CH$_3$)(CH$_3$)-(phenyl)-NH-*	6.8 ± 0.25	<7.6
52	(phenyl)-HN-*	33.23[a]	42.10[a]
53	(morpholine)N-CH$_2$-*	30.0[a]	>34.15[b]
54	Cl-(phenyl)-O-CH$_2$CH$_2$-N(piperazine)N-*	6.9 ± 0.7	24.04[a]
55	(diphenyl)CH-N(piperazine)N-*	1.78 ± 0.17	>37.50[b]
56	HO-CH$_2$CH$_2$-N(piperazine)N-*	>30.6[b]	>30.60[a]
57	(piperidine, H$_3$C, H)N-*	>32[b]	>63.7[a]
58	H$_3$C-(piperidine)N-*	>16.5[b]	>66.1[a]

[a] 50% antiviral activity or toxicity at this dose.
[b] 0–30% antiviral activity or toxicity at this dose.

structures, which showed consistent antiviral activity against a broad-range of laboratory-adapted and primary isolates. We further searched several commercial databases and identified similar analogs, synthesized a series of analogs of **6** and tested them against HIV-1 IIIB. The inhibitory data indicated a trend in SAR, as described below, which may be used as a guiding tool to optimize these two classes of inhibitors.

The SAR analyses of **6** and its analogs (Table 1) reveal that R$_1$ and R$_2$ positions require hydrophobic moieties (**6**, **8**, and **45–47**). Thiophene (**32–38**) containing compounds, although an isostere of furan, showed somewhat reduced activity profile. It appears that R$_1$ position can also accommodate groups like phenyl (**44** and **45**), however, hydrophilic moieties such as pyridine (**7**), piperazine (**11**) and pyrazole (**22**) in R$_2$ position showed detrimental effect on antiviral activity. The R$_2$ position showed trend towards more elongated, bulkier hydrophobic group, such as phenyl (**1**, **2**, **5**, **6**, **8**,

23, **35**, **44**, and **45**); however, the activity was dictated in parallel by the substitutions in the phenyl ring as well as in the quinolinone ring. In terms of phenyl ring substituents, 4-Cl, 4-Br and 4-CH$_3$ showed better activity; however, phenyl group with a bulkier group attached to it such as 4-iPr, 4-OCH$_3$ (**39** and **40**) showed reduced activity. Surprisingly, two compound with furan at R$_1$ and a 3-piperidinyl-4-chloro-phenyl group at R$_2$ and a 4-Cl phenyl at R$_1$ and a bulkier group imidazo[1,2-a]pyridine showed reasonable activity; however, these compounds also showed enhanced toxicity. The quinolinone ring seems very critical for antiviral activity as evidenced in the docked pose (Figure 4) where –NH-moiety of quinolinone ring forms a hydrogen bond with Asn183 located at the hydrophobic cavity of CTD. Similarly, the methyl group at position R$_3$ is also important, which is positioned near a narrow hydrophobic pocket. The SAR analysis also confirms that a bulkier group such as OCH$_3$ (**29–31**, **37** and **38**) and C$_2$H$_5$ (**27** and **28**) showed much reduced activity. It appears that with furyl substituent at R$_1$ and phenyl (and its analogs) at R$_2$, CH$_3$ at position R$_5$ showed equally potent activity (**1–3**, **5**, **36**, and **44**).

The SAR analyses of compounds in Table 2 revealed that a relatively hydrophobic bulkier group is necessary for activity (**50**, **51**, **54**, and **55**). However, relatively weak activity of **49** and **52** could not be explained based on this analysis. Compound **55**, which shows excellent antiviral potency, has the most bulker R group and the end portion is very hydrophobic. It is interesting to note that in the Glide-based docking simulation, the biphenyl moieties of the best pose of **55** make substantial hydrophobic contact with the hydrophobic residues in the cavity (Val165, Thr186 and Leu211) and also make a π–π interaction with the amino acid residue Y169 (Fig. 5). These interactions are missing in other relatively weak active molecules.

3. Discussion and conclusions

The HIV-1 capsid has been identified as a potential target for discovering new inhibitors to fight against AIDS.[28,34,36,38,43] Several groups reported identification of small molecule inhibitors against capsid.[28,34,34,43,44] However, the target of the most active compound, PA-457 (now termed as MPC-4326), which is now in Phase 2b clinical trials (http://www.myriadpharma.com/product-pipeline/clinical/mpc-4326), is the CA-SP1 cleavage site. Summers' group used a computational based docking technique (DOCK 4.0) to screen public domain libraries using a 'β-hairpin cleft' on the surface of the N-terminal domain of the HIV-1 capsid and identified two compounds, CAP-1 and CAP-2. CAP-1 showed virtually no inhibition of virus production; however, the particles produced after treatment was poorly infectious and CAP-2 was toxic.[26,29] Since then there was no report of identification of any small molecule inhibitors against HIV capsid, especially targeted to the CTD of capsid.

In order to fill this gap and to identify new classes of anti-HIV-1 agents, we have used a similar docking-based virtual screening technique used by Summer's group; however, instead of NTD of HIV-1 capsid, we selected the hydrophobic cavity within the CTD of HIV-1 capsid, which had been shown to be large enough to accommodate a 12 residue peptide (CAI) and it's subsequent modified stapled peptide, NYAD-1.[36,38–40] The screening method identified several compounds belonging to two diverse structural classes (**6** and **50**) and inhibited HIV-1 IIIB in low μM potency in an antiviral assay. A subsequent similarity based search on different databases further identified a large number of compounds representing those two diverse structures, many of which also showed low μM potency in an antiviral assay. These compounds showed much better antiviral activity (IC$_{50}$ ~1.06 to 2.16 μM) than CAP-1 or CAP-2. We have tested **6**, **50** and **55** against a wide variety of

Table 3
Antiviral activity of **6**, **50**, and **55** in laboratory-adapted and primary HIV-1 isolates

HIV-1 virus	Subtype	Cell type	Coreceptor	IC_{50} ($\mu M \pm SD$)x		
				6	50	55
Laboratory strains						
IIIB	B	MT-2	X4	1.06 ± 0.05	6.69 ± 0.3	1.78 ± 0.17
MN	B	MT-2	X4	2.88 ± 0.3	7.09 ± 0.72	6.01 ± 0.32
SF2	B	MT-2	R5X4	2.43 ± 0.37	5.72 ± 1.74	3.59 ± 0.25
RF	B	MT-2	X4	1.64 ± 0.05	3.37 ± 0.18	4.01 ± 0.24
BaL	B	PBMC	R5	4.22 ± 0.78	4.9 ± 0.57	3.22 ± 0.7
89.6	B	PBMC	R5X4	6.17 ± 0.5	6.6 ± 0.6	5 ± 1.2
RT-resistant isolate						
AZT-R	B	MT-2	X4	5.77 ± 0.55	3.97 ± 0.67	3.15 ± 0.1
Protease-resistant isolate						
HIV-1$_{RF/L-323-12-3}$	B	MT-2	X4	1.18 ± 0.03	9.05 ± 1.13	5.7 ± 0.6
Primary isolates						
94UG103	A	PBMC	R5X4	3.93 ± 0.25	3.6 ± 0.93	1.24 ± 0.08
92UG037	A	PBMC	R5	-	1.12 ± 0.2	0.73 ± 0.13
92US657	B	PBMC	R5	5.46 ± 0.4	2.7 ± 0.22	4.57 ± 1.55
93IN101	C	PBMC	R5	2.7 ± 0.48	3.36 ± 0.21	2.87 ± 0.14
92UG024	D	PBMC	X4	2.57 ± 0.45	4.9 ± 1.01	3 ± 0.2
93BR020	F	PBMC	R5X4	4.18 ± 1.93	1.93 ± 0.12	5 ± 0.48
RU570	G	PBMC	R5	2.84 ± 0.28	3.9 ± 0.2	2.74 ± 0.42
BCF02	Group (0)	PBMC	R5	6.07 ± 0.21	10.95 ± 2.51	8.95 ± 0.9

Small molecules	CC_{50} (μM) in MT-2	CC_{50} (μM) in PBMC
6	>61.45	>61.45
50	>128.08	>64
55	>37.6	>37.6

Figure 3. The percentage of infectivity of the virions in the supernatant. p24 normalized viruses produced by HIV-1 IIIB infected MT-2 cells treated with different doses of **6** and **55** or AMD3100 (1 μg/mL) were titered on MT-2 cells to calculate $TCID_{50}$.

Figure 4. GLIDE docking pose of **6** in the hydrophobic cavity of the CTD of HIV-1 capsid. The quinolinone NH forms a H-bond with Asn183 indicated in green line. The phenyl and furan group are located in the hydrophobic grove formed by residues Val165, Tyr169, Leu211, and Met215.

primary isolates representing different subtypes and coreceptor use and they showed remarkable activity.

Despite their potential HIV-1 inhibitory activity, we wanted to confirm that these compounds target capsid and inhibit mature-like particles. Indeed **6** and **50** have been shown to be effective in preventing mature like particles as was previously shown by a stapled peptide, NYAD-1, which was shown to bind to the hydrophobic cavity of the CTD by NMR. This data give confidence that these inhibitors have broad anti-HIV-1 activity with promising selectivity index and can be used for further optimization.

A comprehensive SAR analysis of the **6** and **50** type analogs provided useful information for further optimizing this set of molecules. The docking-based analysis of the poses of these two compounds also provided additional information on the critical interaction necessary for the binding of these compounds to the hydrophobic cavity of the CTD of capsid. Future systematic synthesis effort will be geared to get a better understanding on that series.

The data presented in this report provides confidence that the hydrophobic cavity of the CTD of HIV-1 capsid is a potential target to identify antiviral agents and these preliminary data and the SAR study will be the basis of further optimization of these series of inhibitors.

4. Materials and methods

4.1. Molecular modeling and virtual screening

All molecular modeling and virtual screening studies were performed on a HP xw9300 workstation running Red Hat Enterprise

Figure 5. GLIDE docking pose of **55** in the hydrophobic cavity of the CTD of HIV-1 capsid. Two phenyl groups of this molecule are positioned in a hydrophobic group formed by residues Val165, Thr186, Leu211, and Tyr 169. The phenyl moiety of Tyr169 forms π–π interaction with one of the phenyl ring of this molecule (shown in red arrow).

Linux 4.0 and equipped with AMD Opteron dual processors and NVIDIA Quatro FX3400 video card.

4.1.1. Selection of chemical databases

We selected ZINC database[41] for the docking-based virtual screening study. This database contains ~4.6 million pre-filtered compounds in a ready-to-dock stage in 3D format, which can be downloaded free of cost from Brian Shoichet's lab at the University of California at San Francisco (UCSF). The database contains a diverse set of compounds (diversity was assessed based on Tanimoto similarity coefficients) from a large number of vendors as well as compounds from PubChem collections, a component of NIH's Molecular Library Roadmap Initiative. The database was created by filtering out molecules with formula weight >700, calculated Log P >6 and <−4, the number of hydrogen-bond donors >6, the number of hydrogen bond acceptors >11, and the number of rotatable bonds >15. The database contains only molecules having H, C, N, O, F, S, P, Cl, Br, or I atoms. However, exceptions were made by including a number of actual drugs that violate these constraints. The constraints set in the filter are based on the current opinion in the field and is a little more lenient than prescribed by the Lipinski's 'rule of five'.[45,46] We have used a subset of about 100,000 drug-like molecules in our study.

4.1.2. Docking of ligands onto the hydrophobic cavity of the capsid CTD

We used the automated docking software GLIDE 8.0 (Schrödinger, Portland, OR) that applies a two-stage scoring process to sort out the best conformations and orientations of the ligand (defined as pose) based on its interaction pattern with the receptor. GLIDE has been used successfully in drug design.[47–53] The starting point of the docking simulation was the X-ray structure of the CTD of HIV-1 capsid bound with a linear peptide CAI (PDB code: 2buo) available from protein data bank (PDB) at the Research Collaboratory for Structural Bioinformatics (RCSB) which has been extensively used in our research program. We decided to use this specific structure since this is the only ligand (CAI)-bound X-ray structure available for the CTD and provides information on the flexibility of the binding site for ligand binding. The peptide CAI was removed from the protein for docking study. Three-dimensional coordinates of the ligands, their isomeric, ionization and tautomeric states were generated using the LigPrep (including Ionizer) module within the Schrödinger Suite 2008 programs. The protein was prepared using the 'protein preparation tool' and the structures were minimized with Macromodel software from Schrödinger. A grid file encompassing the area in the cavity that contains information on the properties of the associated receptor was created. Conformational flexibility of the ligands was handled via an exhaustive conformational search. Initially, we used Schrödinger's proprietary GlideScore scoring function in standard precision (SP) mode. We selected 2000 top-scored compounds to dock again in extra precision (XP) mode to score the optimized poses. For each ligand 50 different poses were evaluated and 200 top-scored ligands were examined carefully using molecular visualization techniques with 3D CrystalEyes2 stereo eyewear from SteroGraphics Corporation (San Rafael, CA). The poses were selected based on hydrophobic, hydrogen bond and charge–charge interactions. Special attention was also paid to identify poses that may indicate alternative binding modes of the molecules in the hydrophobic cavity. Interaction sites of the active ligands with the CTD from dock poses were mapped using LigandScout 2.0 (Inte:Ligand, Austria).

4.2. Chemistry

All reagents were purchased from commercial suppliers and were used without further purification. Target compounds **1–11**, **27–58** were purchased from commercial sources (Asinex Corp., USA and Chembridge Corp., USA). Compounds **12–26** were synthesized according to the methods described below. The melting points were measured on a Sanyo Gallenkamp melting point

Scheme 1. Reagents: (a) Ac₂O, TEA, MeCN; (b) POCl₃, DMF; (c) HCl, AcOH; (d) R₁–CH₂–NH₂, isopropanol then NaBH₄; (**e**). R₂COOH, TBTU, DCM.

apparatus (Sanyo Gallenkamp, UK). The LC/MS analyses for the compounds were done at Surveyor MSQ (Thermo Finnigan, USA) with APCI ionization. The ^{1}H NMR spectra were recorded on MERCURY plus 400 MHz spectrometer (Varian, Germany). Chemical shift values are given in ppm relative to tetramethylsilane (TMS), with the residual solvent proton resonance as internal standard. High-resolution mass spectra (HRMS) were recorded on a Bruker APEX II ICR-FTMS.

After we have performed a retro synthetic analysis of **6** the focus was on the synthetic Scheme 1 which was validated and allowed us to further explore the chemical space of these quinolin-2-one derivatives. We synthesized **S2**–**S4** by minor modification of the published methods[54,55] as described below. The secondary amines, **S5**–**S7**, were synthesized by a reductive amination of the aldehydes **S4**.[56] Then these three secondary amines were subjected to a TBTU coupling reaction with appropriate acids leading to the desired products, **12**–**26**, with yields ranging from 12% to 78%.

4.2.1. N-Acetyl-p-toluidine (S2)[54,55]

TEA (24.8 g, 0.25 mol) was added at once to a solution of 25.0 g (0.23 mol) p-toluidine in 50 mL of MeCN, followed by a dropwise addition of acetic anhydride (25.2 g, 0.25 mol). The reaction mixture was stirred for 3 h at 50 °C (TLC control). The mixture was cooled to 0 °C and the resulting precipitate was filtered, washed with water (2 × 25 mL) and dried on the air to afford N-acetyl-p-toluidine (**S2**) (25.7 g, 73.4%). m/z (APCI[+]) 150 (M+H[+]). Mp 145–146 °C.

4.2.2. 2-Chloro-6-methylquinoline-3-carbaldehyde (S3)[54,55]

POCl$_3$ (111 mL, 1.19 mol) was added drop wise to DMF (40 mL, 0.51 mol) at 0 °C, followed by a portion wise addition of N-acetyl-p-toluidine (**S2**) (25.7 g, 0.17 mol). The resulting mixture was stirred for 30 min at rt and the reaction mixture heated at 85 °C for 6 h. The resulting solution was cooled to rt and slowly poured into ice-water. The resulting precipitate was filtered, washed with water, dried and crystallized from ethyl acetate to give aldehyde (**S3**) (23.6 g, 66.7%). ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.48 (s, 3H), 7.79 (d, 1H), 7.91 (d, 1H), 8.01 (s, 1H), 8.81 (s, 1H), 10.35 (s, 1H). m/z (APCI[+]) 206 (M+H[+]). mp 124–125 °C.

4.2.3. 6-Methyl-2-oxo-1,2-dihydro-quinoline-3-carbaldehyde (S4)[56]

A solution of 2-chloro-6-methyl-quinoline-3-carbaldehyde (**S3**) (23.6 g, 0.11 mol) in a mixture of AcOH/water (90 mL:10 mL) was heated at 85–90 °C with stirring. After 2 h a precipitation started and the reaction mixture was additionally heated for 4 h at 85–90 °C. The resulting mixture was cooled to 0 °C leading to an intensive precipitate formation. The resulting precipitate was filtered, washed with water, 5% NaHCO$_3$ and again with water, dried on the air to afford the title compound (**S4**) (14.3 g, 68.9%); mp 201–202 °C. ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.35 (s, 3H), 7.25 (d, 1H), 7.49 (d, 1H), 7.71 (s, 1H), 8.39 (s, 1H), 10.21 (s, 1H), 12.05 (br, 1H). m/z (APCI[+]) 188 (M+H[+]).

4.2.4. General procedure to synthesize intermediate compounds (S5–S7)

The suitable amine (3.00 mmol) was added to a solution of 6-methyl-2-oxo-1,2-dihydro-quinoline-3-carbaldehyde (**S4**) (400 mg, 2.13 mmol) in 20 mL of isopropanol. The reaction mixture was refluxed for 7 h, cooled to 0 °C and the resulting precipitate was filtered and washed with hexane (2 × 15 mL) to afford the crude Shiff base. The product was suspended in 15 mL of isopropanol. NaBH$_4$ (100 mg, 2 mmol) was added to the resulting suspension and the mixture stirred for 4 h at rt (TLC control). The reaction mixture was evaporated in vacuo and 20 mL of water was added to res-

idue. The mixture was stirred for 1 h, the precipitate was filtered, washed with water (1 × 10 mL) and dried on the air to give the desired target secondary amines.

4.2.4.1. 3-{[(Furan-2-ylmethyl)-amino]-methyl}-6-methyl-1H-quinolin-2-one (S5).
Compound S5 (119 mg, 72%, mp 129–130 °C) was synthesized according to the general method described above. ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.31 (s, 3H), 3.61 (s, 2H), 3.71 (s, 2H), 6.21 (s, 1H), 6.32 (s, 1H), 7.15 (d, 1H), 7.25 (s, 1H), 7.41 (s, 1H), 7.52 (s, 1H), 7.71 (s, 1H); m/z (APCI[+]) 269 (M+H[+]).

4.2.4.2. 6-Methyl-3-{[(tetrahydro-furan-2-ylmethyl)-amino]-methyl}-1H-quinolin-2-one (S6).
Compound S6 (290 mg, 50%, mp 110–111 °C) was synthesized according to the general procedure described above starting from tetrahdrofuran-2-yl-methylamine (315 mg, 3.11 mmol). ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 1.50 (m, 1H), 1.86 (m, 3H), 2.35 (s, 3H), 2.55 (d, 2H), 3.58 (m, 3H), 3.70 (q, 1H), 3.89 (q, 1H), 7.18 (d, 1H), 7.26 (d, 1H), 7.41 (s, 1H), 7.72 (s, 1H), 11.60 (br, 1H); m/z (APCI[+]) 273 (M+H[+]).

4.2.4.3. 3-[(4-Chloro-benzylamino)-methyl]-6-methyl-1H-quinolin-2-one (S7).
Compound S7 (375 mg, 40%, mp 118–119 °C) was synthesized following the general procedure described above using 4-chlorobenzylamine (425 mg, 3.0 mmol). ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.31 (s, 3H), 3.58 (s, 2H), 3.69 (s, 2H), 7.20 (d, 1H), 7.28 (d, 1H), 7.38 (d, 4H), 7.42 (s, 1H), 7.79 (s, 1H), 11.70 (br, 1H). m/z (APCI[+]) 313 (M+H[+]).

4.3. General procedure to synthesize target compounds (12–26)

The suitable acid (0.5 mmol) was dissolved in DCM (8 mL) and TBTU (193 mg, 0.6 mmol) followed by the addition of TEA (71 mg, 0.7 mmol). The resulting solution was allowed to stir for 30 min at rt and the suitable secondary amine (**S5**–**S7**) (0.5 mmol) was added to the reaction mixture. The stirring was continued for 8 h. The reaction mixture was washed with a solution of K$_2$CO$_3$ (25% in water, 2 × 10 mL), water (1 × 10 mL) and dried over Na$_2$SO$_4$. The solvent was distilled off in vacuo and the residue was crystallized from MeOH to afford the desired target compounds (**12**–**26**).

4.3.1. 4-Fluoro-N-furan-2-ylmethyl-N-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (12)
Compound **12** (119 mg, 72%; mp 129–130 °C) was synthesized according to the general procedure described above, starting from the 4-Fluoro-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.32 (s, 3H), 4.39 (br, 2H), 4.71 (br, 2H), 6.29 (br, 1H), 6.31 (br, 1H), 7.21 (d, 1H, J = 8,5 Hz), 7.31 (br, 1H,), 7.33 (m, 2H,), 7.48 (s, 1H), 7.52 (br, 2H), 7.61 (br, 2H), 11.7 (br, 1H). m/z (APCI[+]) 391 (M+H[+]). HRMS (ESI) m/z calcd for C$_{23}$H$_{19}$FN$_2$O$_3$ (M+H[+]): 391.42; found 391.42.

4.3.2. 3,4-Dichloro-N-furan-2-ylmethyl-N-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (13)
Compound **13** (112 mg, 52%; mp 138–139 °C) was synthesized according to the general procedure described above starting from the 3,4-dichloro-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm): 2.35 (s, 3H), 3.81 (br, 3H), 4.39–4.42 (two broadened signals, 2H, Z/E forms), 4.59–4.71 (two broadened signals, 2H, Z/E forms), 6.31 (br, 1H), 6.39 (br, 1H), 7.25 (d, 1H, J = 8,5 Hz), 7.31 (d, 1H, J = 8,5 Hz), 7.42 (superposition of two broad singlets, 2H), 7.55 (s, 1H), 7.61 (s, 1H), 7.75 (br, 2H), 11.6 (br, 1H). m/z (APCI[+]) 441, 443 (M+H[+]). HRMS (ESI) m/z calcd for C$_{23}$H$_{18}$Cl$_2$N$_2$O$_3$ (M+H[+]): 442.32; found 442.32.

4.3.3. 4-Chloro-*N*-furan-2-ylmethyl-3-hydroxy-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (14)

Compound **14** (277 mg, 22%; mp 160–161 °C) was synthesized according to the general procedure described above starting from the 4-chloro-3-hydroxy-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.31 (s, 3H), 4.32 (br, 2H), 4.65 (br, 2H), 6.31 (br, 1H), 6.39 (br, 1H), 6.99 (br, 2H), 7.19 (d, 1H, J = 8.5 Hz), 7.31 (d, 1H, J = 8.5 Hz), 7.36 (s, 1H), 7.41 (s, 1H), 7.52 (superposition of two singlets, 2H), 10.3 (br, 1H), 11.7 (br, 1H). m/z (APCI$^+$) 423, 425 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{18}Cl_2N_2O_3$ (M+H$^+$): 423.87; found 423.87.

4.3.4. 4-Chloro-*N*-furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-3-piperidin-1-yl-benzamide (15)

Compound **15** (102 mg, 48%; mp 150–151 °C) was synthesized according to the general procedure described above starting from the 4-chloro-3-piperidin-1-yl-benzoic acid and amine (**S5**). NMR ^{1}H (400 MHz, DMSO-d_6 ppm: 1.5 (br, 6H), 2.32 (s, 3H), 2.72–2.91 (two broad peak 4H, *Z/E* forms), 4.22–4.41 (two broadened signals, 2H, *Z/E* forms), 4.61–4.75 (two broadened signals, 2H, *Z/E* forms), 6.31 (br, 1H), 6.39 (br, 1H), 7.15 (br, 2H), 7.21 (d, 1H, J = 8.5 Hz), 7.31 (d, 1H, J = 8.5 Hz), 7.41 (br, 1H), 7.49 (s, 1H), 7.61 (s, 1H), 7.62 (s, 1H), 11.7 (br, 1H). m/z (APCI$^+$) 490, 492 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{28}H_{28}ClN_3O_3$ (M+H$^+$): 491.01; found 491.01.

4.3.5. 4-Cyano-*N*-furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (16)

Compound **16** (127 mg, 63%; mp 220–221 °C) was synthesized according to the general procedure described above starting from the 4-cyano-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.32 (s, 3H), 4.22–4.51 (two broadened signals, 2H, *Z/E* forms), 4.51–4.78 (two broadened signals, 2H, *Z/E* forms), 6.31 (br, 1H), 6.41 (br, 1H), 7.21 (br, 1H), 7.31 (d, 1H, J = 8.5 Hz), 7.51 (s, 1H), 7.59 (s, 1H), 7.62 (br, 2H), 7.72 (br, 1H), 7.81–8.05 (two broadened signals, 2H), 11.7 (br, 1H). m/z (APCI$^+$) 398 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{24}H_{19}N_3O_3$ (M+H$^+$): 398.44; found 398.44.

4.3.6. 3-Chloro-4-fluoro-*N*-furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (17)

Compound **17** (121 mg, 62%; mp 132–134 °C) was synthesized according to the general procedure described above starting from the 3-chloro-4-fluoro-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.32 (s, 3H), 4.41 (br, 2H), 4.61 (br, 2H), 6.31 (br, 1H), 6.41 (br, 1H), 7.21 (d, 1H, J = 8.5 Hz), 7.35 (d, 1H, J = 8.5 Hz), 7.51 (br, 3H), 7.59 (s, 1H), 7.62 (s, 1H), 7.81 (br, 1H), 11.6 (br, 1H). m/z (APCI$^+$) 425, 427 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{18}ClFN_2O_3$ (M+H$^+$): 425.87; found 425.87.

4.3.7. 3,5-Dichloro-*N*-furan-2-ylmethyl-4-hydroxy-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (18)

Compound **18** (33 mg, 18%; mp 188–189 °C) was synthesized according to the general procedure described above starting from the 3,5-dichloro-4-hydroxy-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.31 (s, 3H), 4.41 (br, 2H), 4.61 (br, 2H), 6.35 (br, 1H), 6.41 (br, 1H), 7.21 (d, 1H, J = 8.5 Hz), 7.32 (d, 1H, J = 8.5 Hz), 7.51 (br, 1H), 7.55 (br, 2H), 7.61 (s, 1H), 7.67 (s, 1H), 10.05 (br, 1H), 11.6 (br, 1H). m/z (APCI$^+$) 457, 459 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{18}Cl_2N_2O_4$ (M+H$^+$): 458.32; found 458.32.

4.3.8. *N*-Furan-2-ylmethyl-6-methoxy-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-nicotinamide (19)

Compound **19** (94 mg, 52%; mp 173–175 °C) was synthesized according to the general procedure described above starting from the 6-methoxy-nicotinic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.41 (s, 3H), 3.91 (br 3H), 4.41 (br, 2H), 4.68 (br, 2H), 6.31 (br, 1H), 6.39 (br, 1H), 6.89 (d, 1H, J = 8.5 Hz), 7.22 (d, 1H, J = 8.5 Hz), 7.31 (d, 1H, J = 8.5 Hz), 7.51 (s, 1H), 7.59 (s, 1H), 7.61 (s, 1H), 7.81 (br, 1H), 8.41 (br, 1H)11.7 (br, 1H). m/z (APCI$^+$) 404 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{21}N_3O_4$ (M+H$^+$): 404.45; found 404.45.

4.3.9. 4-Dimethylamino-*N*-furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (20)

Compound **20** (96 mg, 53%; mp 147–148 °C) was synthesized according to the general procedure described above starting from the 4-dimethylamino-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.31 (s, 3H), 2.92 (s, 6H), 4.38 (s, 2H), 4.68 (s, 2H), 6.32 (br, 1H), 6.38 (br, 1H), 6.71 (d, 2H, J = 8.5 Hz), 7.21 (d, 1H, J = 8.5 Hz), 7.29 (d, 1H, J = 8.5 Hz), 7.39 (br, 2H, J = 8.5 Hz), 7.41 (s, 1H), 7.61 (br, 2H), 7.62 (br, 1H), 11.5 (br, 1H). m/z (APCI$^+$) 416 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{25}H_{25}N_3O_3$ (M+H$^+$): 416.50; found 416.50.

4.3.10. 3-Chloro-*N*-furan-2-ylmethyl-4-hydroxy-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (21)

Compound **21** (24 mg, 12%; mp 180–182 °C) was synthesized according to the general procedure described above starting from the 3-chloro-4-hydroxy-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.35 (s, 3H), 4.35 (s, 2H), 4.62 (s, 2H), 6.31 (br, 1H), 6.41 (br, 1H), 6.99 (br d, 1H, J = 8.5 Hz), 7.22 (d, 1H, J = 8.5 Hz), 7.31 (d, 1H, J = 8.5 Hz), 7.35 (s, 1H), 7.51 (s, 1H), 7.53 (br, 1H), 7.58 (s, 1H), 7.61 (s, 1H), 10.5 (br, 1H), 11.6 (br, 1H). m/z (APCI$^+$) 423, 424 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{19}ClN_2O_4$ (M+H$^+$): 423.88; found 423.88.

4.3.11. 1-Methyl-1*H*-pyrazole-4-carboxylic acid furan-2-ylmet hyl-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-amide (22)

Compound **22** (26 mg, 12%; mp 230–231 °C) was synthesized according to the general procedure described above starting from the 1-methyl-1*H*-pyrazole-4-carboxylic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.31 (s, 3H), 3.81 (br 3H), 4.41 (br, 2H), 4.75 (br, 2H), 6.31 (br, 1H), 6.35 (br, 1H), 7.19 (d, 1H, J = 8,5 Hz), 7.25 (d, 1H, J = 8,5 Hz), 7.41 (s, 1H), 7.46 (s, 1H), 7.52 (br, 1H), 7.62 (br, 1H), 8.05 (br, 1H), 11.7 (br, 1H). m/z (APCI$^+$) 377 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{21}H_{20}N_4O_3$ (M+H$^+$): 377.43; found 377.43.

4.3.12. 3,4-Difluoro-*N*-furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-benzamide (23)

Compound **23** (99 mg, 54%; mp 142–114 °C) was synthesized according to the general procedure described above starting from the 3,4-difluoro-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.31 (s, 3H), 4.41 (br peak, 2H), 4.61 (br peak, 2H), 6.27 (br peak, 1H), 6.30 (br peak, 1H), 7.19 (d, 1H, J = 8,5 Hz), 7.29 (d, 1H, J = 8,5 Hz), 7.39 (s, 1H), 7.48 (s, 1H), 7.52 (br peak, 1H), 7.62 (br peak, 2H), 11.6 (br peak, 1H). m/z (APCI$^+$) 409 (M+H$^+$). HRMS (ESI) m/z calcd for $C_{23}H_{18}F_2N_2O_3$ (M+H$^+$): 409.42; found 409.42.

4.3.13. *N*-Furan-2-ylmethyl-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-4-sulfamoyl-benzamide (24)

Compound **24** (26 mg, 13%; mp 248–249 °C) was synthesized according to the general procedure described above starting from the 4-sulfamoyl-benzoic acid and amine (**S5**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.35 (s, 3H), 4.29–4.38 (two br peaks, 2H, *Z/E* forms), 4.41–4.71 (two br peaks, 2H *Z/E* forms), 6.29 (br, 1H), 6.37 (br, 1H), 7.21 (d, 1H, J = 8.5 Hz), 7.29 (d, 1H, J = 8.5 Hz), 7.49 (s, 1H), 7.52 (s, 1H), 7.61 (br, 2H), 7.68 (br, 1H), 7.88 (br, 2H). m/z

(APCI+) 452 (M+H+). HRMS (ESI) *m/z* calcd for $C_{23}H_{21}N_3O_5S$ (M+H+): 452.51; found 452.51.

4.3.14. 4-Chloro-*N*-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-*N*-(tetrahydro-furan-2-lmethyl)-benzamide (25)

Compound **25** (51 mg, 25%; mp 223–225 °C) was synthesized according to the general procedure described above starting from the 4-chloro-benzoic acid and amine (**S6**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 1.15–1.95 (two broad peaks, 4H) , 2.35 (s, 3H), 3.35 (br, 1H), 3.70 (br, 2H), 4.09 (br, 2H) 4.55 (br, 2H) 7.21 (d, 1H), 7.29 (d, 1H), 7.35–7.54 (br 5H), 7.66 (br s, 1H), 11.65 (br, 1H). *m/z* (APCI+) 411, 413 (M+H+). HRMS (ESI) *m/z* calcd for $C_{23}H_{23}ClN_2O_3$ (M+H+): 411.91; found 411.911.

4.3.15. 8-Methyl-imidazo[1,2-*a*]pyridine-2-carboxylic acid (4-chloro-benzyl)-(6-methyl-2-oxo-1,2-dihydro-quinolin-3-ylmethyl)-amide (26)

Compound **26** (47 mg, 20%; mp 250–251 °C) was synthesized according to the general procedure described above starting from the 8-methyl-imidazo[1,2-*a*]pyridine-2-carboxylic acid and amine (**S7**). ^{1}H NMR (400 MHz, DMSO-d_6 ppm: 2.35 (s, 6H), 4.30–4.80 (two br peaks, 2H, *Z/E* forms), 5.10–5.60 (two br peaks, 2H, *Z/E* forms), 6.80 (br, 1H), 7.05 (br, 1H), 7.10–7.45 (br m, 7H), 7.61 (br, 1H), 8.35 (br, 2H), 11.62 (br, 1H). *m/z* (APCI+) 471, 473 (M+H+). HRMS (ESI) *m/z* calcd for $C_{27}H_{23}ClN_4O_2$ (M+H+): 471.97; found 471.97.

4.4. Electron microscopy to study inhibition of in vitro assembly by small molecules

In vitro assembly systems were set up as previously reported.[39] Briefly, stock proteins were adjusted to the appropriate concentration (25 μM for Gag proteins and 50 μM for CA proteins) with the Na_2HPO_4 buffer at pH 8.0. After addition of 5% total *Escherichia coli* RNA (RNA/protein = 1:20 by weight), incubation with or without varied doses of NYAD-1 as positive control and **6** and **50** as test samples for 30 min at 4 °C, the samples were dialyzed overnight in Na_2HPO_4 buffer at pH 8.0 containing 100 mM of NaCl at 4 °C. For assembly of CA mature-like particles, addition of 5% total *E. coli* RNA was omitted. Negative staining was used to check the assembly. Carbon-coated copper grids (200 mesh size; EM Sciences) were treated with 20 μl of poly-ʟ-lysine (1 mg/mL; Sigma) for 2 min. Twenty microliters of reaction solution were placed onto the grid for 2 min. Spotted grids were then stained with 30 μl of uranyl acetate solution for 2 min. Excess stain was removed, and grids were air-dried. Specimens were examined with a TECNAI G^2 electron microscope at 80 Kv.

4.5. Measurement of antiviral activity

The inhibitory activity of small molecules on infection by laboratory-adapted HIV-1 strains was determined as previously described.[39] In brief, 1×10^4 MT-2 cells were infected with HIV-1 at 100 TCID$_{50}$ (50% tissue culture infective dose) (0.01MOI) in 200 μl RPMI 1640 medium containing 10% FBS in the presence or absence of small molecules at graded concentrations overnight. The culture supernatants were then removed and fresh media containing freshly prepared test small molecules were added. On the fourth day post-infection, 100 μl of culture supernatants were collected from each well, mixed with equal volume of 5% Triton X-100 and tested for p24 antigen by ELISA.

The inhibitory activity of selected lead compounds (**6**, **50** and **55**) on infection by primary HIV-1 isolates was determined as previously described.[39] PBMCs were isolated from the blood of healthy donors at the New York Blood Center by standard density gradient centrifugation using Histopaque-1077 (Sigma–Aldrich). The cells

were cultured at 37 °C for 2 h. Nonadherent cells were collected and resuspended at 5×10^6 cells/mL RPMI-1640 medium containing 10% FBS, 5 μg/mL PHA, and 100 U/mL IL-2 (Sigma–Aldrich), followed by incubation at 37 °C for 3 days. The PHA-stimulated cells (5×10^4 cells) were infected with primary HIV-1 isolates at 500 TCID$_{50}$ (0.01 MOI) in the absence or presence of small molecule inhibitors at graded concentrations. Culture media were changed every 3 days and replaced with fresh media containing freshly prepared inhibitor. The supernatants were collected 7 days post-infection and tested for p24 antigen by ELISA. The percent inhibition of p24 production and IC$_{50}$ values were calculated by the GraphPad Prism software (GraphPad Software Inc.).

4.6. Cytotoxicity assay

Cytotoxicity of small molecules in MT-2 cells and PBMC was measured by the XTT [(sodium 3′-(1-(phenylamino)-carbonyl)-3,4-tetrazolium-bis(4-methoxy-6-nitro) bezenesulfonic acid hydrate)] method as previously described.[39] Briefly, for MT-2 cells, 100 μl of a small molecule at graded concentrations was added to an equal volume of cells (1×10^5 cells/mL) in 96-well plates followed by incubation at 37 °C for 4 days, which ran parallel to the neutralization assay in MT-2 (except medium was added instead of virus). In the case of PBMC, 5×10^5 cells/mL were used and the cytotoxicity was measured after 7 days. After addition of XTT (PolySciences, Inc.), the soluble intracellular formazan was quantitated colorimetrically at 450 nm 4 h later with a reference at 620 nm. The percent of cytotoxicity and the CC$_{50}$ values were calculated as above.

4.7. Infectivity assay

In these assays we wanted to measure the infectivity potential of the virions released by treating cells infected with HIV-1 by **6** and **55**. Briefly, 5×10^4/mL MT-2 cells were infected with HIV-1 IIIB (m.o.i. = 0.01) in the presence of 5 μM, 2.5 μM and 1.3 μM of small molecules **6** and 4 μM, 2 μM and 1 μM of **55**. Control cells were untreated or treated with 1ug/mL of AMD3100 (CXCR4 receptor inhibitor). Following overnight incubation the medium was completely removed and replaced with fresh medium. On the fourth day post-infection the supernatants were collected and filtered with a 0.45 μm PVDF membrane.

One aliquot of the supernatants from each sample was mixed 1:1 with a solution of 5% Triton X-100 for p24 quantification, and stored at 4 °C, another aliquot was immediately frozen at −80 °C and used to compare the infectivity of the viral particles released by **6** and **55** treated cells to the viral particles released by untreated cells. P24 was quantified by sandwich-ELISA then the viral samples were normalized for the p24 content and titered by infecting MT-2 cells to calculate the TCID$_{50}$. Following overnight incubation 3/4 of the medium containing the *inoculum* was replaced with fresh medium. On the fourth day post infection supernatants were collected for p24 quantification by sandwich-ELISA and the TCID$_{50}$ was calculated by the Spearman–Karber statistical method.

References and notes

1. Briggs, J. A.; Wilk, T.; Welker, R.; Krausslich, H. G.; Fuller, S. D. *EMBO J.* **2003**, *22*, 1707.
2. Briggs, J. A.; Grunewald, K.; Glass, B.; Forster, F.; Krausslich, H. G.; Fuller, S. D. *Structure* **2006**, *14*, 15.

3. Li, S.; Hill, C. P.; Sundquist, W. I.; Finch, J. T. *Nature* **2000**, *407*, 409.
4. Ganser, B. K.; Li, S.; Klishko, V. Y.; Finch, J. T.; Sundquist, W. I. *Science* **1999**, *283*, 80.
5. Ganser-Pornillos, B. K.; Cheng, A.; Yeager, M. *Cell* **2007**, *131*, 70.
6. Ako-Adjei, D.; Johnson, M. C.; Vogt, V. M. *J. Virol.* **2005**, *79*, 13463.
7. von Schwedler, U. K.; Stray, K. M.; Garrus, J. E.; Sundquist, W. I. *J. Virol.* **2003**, *77*, 5439.
8. Abdurahman, S.; Hoglund, S.; Goobar-Larsson, L.; Vahlne, A. *J. Gen. Virol.* **2004**, *85*, 2903.
9. Chien, A. I.; Liao, W. H.; Yang, D. M.; Wang, C. T. *Virology* **2006**, *348*, 84.
10. Douglas, C. C.; Thomas, D.; Lanman, J.; Prevelige, P. E., Jr. *Biochemistry* **2004**, *43*, 10435.
11. Forshey, B. M.; von Schwedler, U. K.; Sundquist, W. I.; Aiken, C. *J. Virol.* **2002**, *76*, 5667.
12. Ganser-Pornillos, B. K.; von Schwedler, U. K.; Stray, K. M.; Aiken, C.; Sundquist, W. I. *J. Virol.* **2004**, *78*, 2545.
13. Joshi, A.; Nagashima, K.; Freed, E. O. *J. Virol.* **2006**, *80*, 7939.
14. del Alamo, M.; Mateu, M. G. *J. Mol. Biol.* **2005**, *345*, 893.
15. Scholz, I.; Arvidson, B.; Huseby, D.; Barklis, E. *J. Virol.* **2005**, *79*, 1470.
16. Chang, Y. F.; Wang, S. M.; Huang, K. J.; Wang, C. T. *J. Mol. Biol.* **2007**, *370*, 585.
17. Abdurahman, S.; Hoglund, S.; Hoglund, A.; Vahlne, A. *Retrovirology* **2007**, *4*, 19.
18. Abdurahman, S.; Youssefi, M.; Hoglund, S.; Vahlne, A. *Retrovirology* **2007**, *4*, 69.
19. Yamashita, M.; Emerman, M. *J. Virol.* **2004**, *78*, 5670.
20. Vogt, V. M. *Nat. Struct. Mol. Biol.* **2005**, *12*, 638.
21. Li, F.; Wild, C. *Curr. Opin. Investig. Drugs* **2005**, *6*, 148.
22. Li, J.; Tang, S.; Hewlett, I.; Yang, M. *Infect. Disord. Drug Targets* **2007**, *7*, 238.
23. Niedrig, M.; Gelderblom, H. R.; Pauli, G.; Marz, J.; Bickhard, H.; Wolf, H.; Modrow, S. *J. Gen. Virol.* **1994**, *75*, 1469.
24. Hoglund, S.; Su, J.; Reneby, S. S.; Vegvari, A.; Hjerten, S.; Sintorn, I. M.; Foster, H.; Wu, Y. P.; Nystrom, I.; Vahlne, A. *Antimicrob. Agents Chemother.* **2002**, *46*, 3597.
25. Garzon, M. T.; Lidon-Moya, M. C.; Barrera, F. N.; Prieto, A.; Gomez, J.; Mateu, M. G.; Neira, J. L. *Protein Sci.* **2004**, *13*, 1512.
26. Tang, C.; Loeliger, E.; Kinde, I.; Kyere, S.; Mayo, K.; Barklis, E.; Sun, Y.; Huang, M.; Summers, M. F. *J. Mol. Biol.* **2003**, *327*, 1013.
27. Sakalian, M.; McMurtrey, C. P.; Deeg, F. J.; Maloy, C. W.; Li, F.; Wild, C. T.; Salzwedel, K. *J. Virol.* **2006**, *80*, 5716.
28. Li, F.; Goila-Gaur, R.; Salzwedel, K.; Kilgore, N. R.; Reddick, M.; Matallana, C.; Castillo, A.; Zoumplis, D.; Martin, D. E.; Orenstein, J. M.; Allaway, G. P.; Freed, E. O.; Wild, C. T. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 13555.
29. Kelly, B. N.; Kyere, S.; Kinde, I.; Tang, C.; Howard, B. R.; Robinson, H.; Sundquist, W. I.; Summers, M. F.; Hill, C. P. *J. Mol. Biol.* **2007**, *373*, 355.
30. Martin, D. E.; Blum, R.; Wilton, J.; Doto, J.; Galbraith, H.; Burgess, G. L.; Smith, P. C.; Ballow, C. *Antimicrob. Agents Chemother.* **2007**, *51*, 3063.
31. Stoddart, C. A.; Joshi, P.; Sloan, B.; Bare, J. C.; Smith, P. C.; Allaway, G. P.; Wild, C. T.; Martin, D. E. *PLoS One* **2007**, *2*, e1251.

32. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. *Antimicrob. Agents Chemother.* **2007**, *51*, 3574.
33. Adamson, C. S.; Ablan, S. D.; Boeras, I.; Goila-Gaur, R.; Soheilian, F.; Nagashima, K.; Li, F.; Salzwedel, K.; Sakalian, M.; Wild, C. T.; Freed, E. O. *J. Virol.* **2006**, *80*, 10957.
34. Zhou, J.; Yuan, X.; Dismuke, D.; Forshey, B. M.; Lundquist, C.; Lee, K. H.; Aiken, C.; Chen, C. H. *J. Virol.* **2004**, *78*, 922.
35. Zhou, J.; Chen, C. H.; Aiken, C. *J. Virol.* **2006**, *80*, 12095.
36. Sticht, J.; Humbert, M.; Findlow, S.; Bodem, J.; Muller, B.; Dietrich, U.; Werner, J.; Krausslich, H. G. *Nat. Struct. Mol. Biol.* **2005**, *12*, 671.
37. Schafmeister, C. E.; Po, J.; Verdine, G. L. *J. Am. Chem. Soc.* **2000**, *122*, 5891.
38. Ternois, F.; Sticht, J.; Duquerroy, S.; Krausslich, H. G.; Rey, F. A. *Nat. Struct. Mol. Biol.* **2005**, *12*, 678.
39. Zhang, H.; Bhattacharya, S.; Tong, X.; Waheed, A. A.; Hong, A.; Heck, S.; Curreli, F.; Goger, M.; Cowburn, D.; Freed, E. O.; Debnath, A. K. *J. Mol. Biol.* **2008**, *378*, 565.
40. Bhattacharya, S.; Zhang, H.; Debnath, A. K.; Cowburn, D. *J. Biol. Chem.* **2008**, *283*, 16274.
41. Irwin, J. J.; Shoichet, B. K. *J. Chem. Inf. Model.* **2005**, *45*, 177.
42. Gross, I.; Hohenberg, H.; Krausslich, H. G. *Eur. J. Biochem.* **1997**, *249*, 592.
43. Yu, D.; Wild, C. T.; Martin, D. E.; Morris-Natschke, S. L.; Chen, C. H.; Allaway, G. P.; Lee, K. H. *Expert Opin. Investig. Drugs* **2005**, *14*, 681.
44. Qian, K.; Kuo, R. Y.; Chen, C. H.; Huang, L.; Morris-Natschke, S. L.; Lee, K. H. *J. Med. Chem.* **2010**, *53*, 3133.
45. Lipinski, C. A. *J. Pharmacol. Toxicol. Methods* **2000**, *44*, 235.
46. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug Delivery Rev.* **2001**, *46*, 3.
47. Podvinec, M.; Lim, S. P.; Schmidt, T.; Scarsi, M.; Wen, D.; Sonntag, L. S.; Sanschagrin, P.; Shenkin, P. S.; Schwede, T. *J. Med. Chem.* **2010**, *53*, 1483.
48. Kim, Y. A.; Sharon, A.; Chu, C. K.; Rais, R. H.; Al Safarjalani, O. N.; Naguib, F. N. M.; el Kouni, M. H. *Biochem. Pharmacol.* **2007**, *73*, 1558.
49. Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.; Greedy, B.; Lawrence, H. R.; Yip, M. L. R.; Jove, R.; McLaughlin, M. M.; Lawrence, N. J.; Sebti, S. M.; Turkson, J. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 7391.
50. Tripathy, R.; Ghose, A.; Singh, J.; Bacon, E. R.; Angeles, T. S.; Yang, S. X.; Albom, M. S.; Aimone, L. D.; Herman, J. L.; Mallamo, J. P. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1793.
51. Lyne, P. D.; Lamb, M. L.; Saeh, J. C. *J. Med. Chem.* **2006**, *49*, 4805.
52. Bembenek, S. D.; Keith, J. M.; Letavic, M. A.; Apodaca, R.; Barbier, A. J.; Dvorak, L.; Aluisio, L.; Miller, K. L.; Lovenberg, T. W.; Carruthers, N. I. *Bioorg. Med. Chem.* **2008**, *16*, 2968.
53. Ravindranathan, K. P.; Mandiyan, V.; Ekkati, A. R.; Bae, J. H.; Schlessinger, J.; Jorgensen, W. L. *J. Med. Chem.* **2010**, *53*, 1662.
54. Srivastava, A.; Singh, M. K.; Singh, R. M. *Indian J. Chem., Sect. B* **2006**, *45*, 292.
55. Meth-Cohn, O.; Narine, B.; Tarnowski, B. *J. Chem. Soc., Perkin Trans. 1* **1981**, 1520.
56. Pawarr, R. A.; Bajare, P. B.; Mundade, S. B. *J. Indian Chem. Soc.* **1990**, *67*, 685.